Overview
- Health Secretary David Kershenobich said the domestically developed Patria shot could be adapted to address diseases such as yellow fever.
- The vaccine is currently undergoing required testing with Cofepris as it seeks sanitary registration for COVID-19 use.
- Officials highlighted that Patria uses a viral‑vector platform distinct from mRNA vaccines, which they view as offering repurposing potential.
- Mexico continues to administer Moderna and Pfizer RNA vaccines for COVID-19 while training personnel and seeking RNA technology transfer.
- For the current season, authorities reported a little over 10 million COVID-19 doses for high‑risk groups and 40 million influenza doses in stock.